SGLT2 inhibitor empagliflozin downregulates miRNA-34a-5p and targets GREM2 to inactivate hepatic stellate cells and ameliorate non-alcoholic fatty liver disease-associated fibrosis

Analysis of the Human Tissue-specific Expression by Genome-wide Integration of Transcriptomics and Antibody-based Proteomics

Linn Fagerberg, Björn M. Hallström, Per Oksvold et al. · Molecular & Cellular Proteomics · 2013 · 3.8K citations · Full text

Life Sciences, Biochemistry, Molecular Biology +17

Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)

Mohammad Shafi Kuchay, Sonal Krishan, Sunil Kumar Mishra et al. · Diabetes Care · 2018 · 629 citations

Medicine, Pharmacology, Pharmacotherapy +17

Protocol for Primary Mouse Hepatocyte Isolation

Meital Charni‐Natan, Ido Goldstein · STAR Protocols · 2020 · 415 citations · Full text

Engineering, Bioengineering, Cell Biology +13

The role of TGFβ1 in initiating hepatic stellate cell activation in vivo

Claus Hellerbrand, Branko Stefanovic, Frank J. Giordano et al. · Journal of Hepatology · 1999 · 389 citations

Life Sciences, Cell Biology, Molecular Biology +12

Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study

Jan W. Eriksson, Per Lundkvist, Per‐Anders Jansson et al. · Diabetologia · 2018 · 387 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16